Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenues
Royalty and licensing revenue	$ 6,257,688	$ 6,128,601	$ 10,456,188	$ 9,874,851
Treatment investment revenue	0	563,461	0	643,956
Grant and contract revenue	54,843	81,803	138,929	1,690,602
Total revenue	6,312,531	6,773,865	10,595,117	12,209,409
Operating expenses
General and administrative	2,836,162	2,796,539	5,409,473	6,178,609
Research and development	558,311	1,633,386	1,979,296	5,200,649
Sales and marketing	1,746,917	0	2,823,444	0
Royalty expense	1,402,749	934,407	2,336,754	1,248,075
Total operating expenses	6,544,139	5,364,332	12,548,967	12,627,333
Income (loss) from operations	(231,608)	1,409,533	(1,953,850)	(417,924)
Other income (expense)
Interest income	11,494	122,674	88,093	244,269
Gain (loss) on foreign exchange	3,909	(10,839)	3,909	(40,997)
Total other income	15,403	111,835	92,002	203,272
Income (loss) before income taxes	(216,205)	1,521,368	(1,861,848)	(214,652)
Income tax (expense) benefit	0	56,805	(39,000)	56,805
Net income (loss)	(216,205)	1,578,173	(1,900,848)	(157,847)
Other comprehensive loss:
Foreign currency translation adjustment	(17,229)	0	(310,720)	0
Total other comprehensive loss	(17,229)	0	(310,720)	0
Comprehensive income (loss)	$ (233,434)	$ 1,578,173	$ (2,211,568)	$ (157,847)
Net income (loss) per share of common stock:
Basic (in dollars per share)	$ (0.05)	$ 0.39	$ (0.45)	$ (0.04)
Diluted (in dollars per share)	$ (0.05)	$ 0.31	$ (0.45)	$ (0.04)
Weighted average shares outstanding used to compute net income (loss) per share:
Basic (in shares)	4,258,105	3,995,669	4,241,423	3,952,773
Diluted (in shares)	4,258,105	5,128,575	4,241,423	3,952,773